Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing Survivin

Journal of Pineal Research

Volumn 55, Issue 2, 2013, Pages 184-194

  Fan, Lulu ^a   Sun, Guoping ^a   Ma, Tai ^a   Zhong, Fei ^a   Lei, Yu ^a   Li, Xiaoqiu ^a   Wei, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Endoplasmic reticulum stress; Hepatocellular carcinoma; Melatonin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DOXORUBICIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MELATONIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SURVIVIN; TUNICAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT; BIRC5 PROTEIN, HUMAN; DDIT3 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMA CELL; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; PHYSIOLOGY; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM STRESS; HEP G2 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MELATONIN; TRANSCRIPTION FACTOR CHOP; TUNICAMYCIN; UP-REGULATION;

EID: 84885176479     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12061     Document Type: Article

References (37)

1. WALY RAPHAEL S, YANGDE Z, YUXIANG C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012; 2012:421673.
2. FORNER A, LLOVET JM, BRUIX J. Hepatocellular carcinoma. Lancet 2012; 379:1245-1255.
3. CABRERA R, NELSON DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31:461-476.
4. KAPOOR A, SANYAL AJ. Endoplasmic reticulum stress and the unfolded protein response. Clin Liver Dis 2009; 13:581-590.
5. CHAKABRTI A, CHEN AW, VARNER JD. A review of the mammalian unfolded protein response. Biotechnol Bioeng 2011; 108:2777-2793.
6. RASHEVA VI, DOMINGOS PM. Cellular responses to endoplasmic reticulum stress and apoptosis. Apoptosis 2009; 14:996-1007.
7. PARMAR VM, SCHRODER M. Sensing endoplasmic reticulum stress. Adv Exp Med Biol 2012; 738:153-168.
8. SCHONTHAL AH. Targeting endoplasmic reticulum stress for cancer therapy. Front Biosci (Schol Ed) 2012; 4:412-431.
9. LEE AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 2007; 67:3496-3499.
10. MA Y, HENDERSHOT LM. The role of the unfolded protein response in tumour development: Friend or foe? Nat Rev Cancer 2004; 4:966-977.
11. BROWN JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002; 1:453-458.
12. FENG R, ZHAI WL, YANG HY et al. Induction of ER stress protects gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation of p38 MAPK. Biochem Biophys Res Commun 2011; 406:299-304.
13. CHEN R, DAI RY, DUAN CY et al. Unfolded protein response suppresses cisplatin-induced apoptosis via autophagy regulation in human hepatocellular carcinoma cells. Folia Biol (Praha) 2011; 57:87-95.
14. STEHLE JH, SAADE A, RAWASHDEH O et al. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011; 51:17-43.
15. REITER RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12:151-180.
16. REITER RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993; 49:654-664.
17. ARENDT J. Melatonin, circadian rhythms, and sleep. N Engl J Med 2000; 343:1114-1116.
18. GONZALES A, Del CASTILLO-VAQUERO A, MIRO-MORAN A et al. Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology. J Pineal Res 2011; 50:250-260.
19. CABRERA J, NEGRIN G, ESTEVEZ F et al. Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. J Pineal Res 2010; 49:45-54.
20. KIM JH, JEONG SJ, KIM B et al. Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells. J Pineal Res 2012; 52:244-252.
21. LIVRAGHI T,MAKISALO H, LINE PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011; 100:22-29.
22. WILSON WR, HAY MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11:393-410.
23. NAGASAWA H. Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery: drug discovery for targeting the tumor microenvironment. J Pharmacol Sci 2011; 115:446-452.
24. HSU JL, CHIANG PC, GUH JH. Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78. Naunyn Schmiedebergs Arch Pharmacol 2009; 380:373-382.
25. SCRIVEN P, BROWN NJ, POCKLEY AG et al. The unfolded protein response and cancer: a brighter future unfolding? J Mol Med (Berl) 2007; 85:331-341.
26. TAN DX, CHEN LD, POEGGELER B et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60
27. MOTILVA V, GARCIA-MAURINO S, TALERO E et al. New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin. J Pineal Res 2011; 51:44-60.
28. GALANO A, TAN DX, REITER RJ. Melatonin as a naturally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51:1-16.
29. LISSONI P, BARNI S, MANDALA M et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999; 35:1688-1692.
30. FAN LL, SUN GP, WEI W et al. Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J Gastroenterol 2010; 16:1473-1481.
31. CASADO-ZAPICO S, RODRIGUZE-BLANCO J, GARCIA-SANTOS G et al. Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res 2010; 48:72-80.
32. REITER RJ, TAN DX, SAINZ RM et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54:1299-1321.
33. MARONE R, CMILJANOVIC V, GIESE B et al. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784:159-185.
34. PAZ-ARES L, BLANCO-APARICIO C, GARCIA-CARBONERO R et al. Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol 2009; 11:572-579.
35. SAMUELS Y, ERICSON K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18:77-82.
36. KIM R, EMI M, TANABE K et al. Role of the unfolded protein response in cell death. Apoptosis 2006; 11:5-13.
37. SOHN J, KHAOUSTOV VI, XIE Q et al. The effect of ursodeoxycholic acid on the survivin in thapsigargin-induced apoptosis. Cancer Lett 2003; 191:83-92.